Search Results

You are looking at 1 - 10 of 12 items for :

  • "Parenteral iron" x
Clear All
Full access

Christopher A. Laman, Scott B. Silverstein and George M. Rodgers

—results of a multicenter, randomized trial [abstract] . Blood 2004 ; 104 ( Part 2 ): 10b . 4 Silverstein SB Rodgers GM . Parenteral iron therapy options . Am J Hematol 2004 ; 76 : 74 – 78 . 5 Bailie GR Clark JA Lane CE

Full access

John Glaspy

anemia frequently observed in patients with chronic illnesses, including cancer, 1 – 5 coupled with the development of parenteral iron preparations that have a more favorable safety profile than the early iron dextran products, 6 – 8 has increased

Full access

Anat Gafter-Gvili, David P. Steensma and Michael Auerbach

/or chemotherapy-induced anemia in patients treated with erythropoiesis-stimulating agents . Commun Oncol 2011 ; 8 : 270 – 278 . 12. Steensma D Sloan J Dakhil S . Phases III, randomized study of the effects of parenteral iron, oral iron, or no iron

Full access

The University of Alabama at Birmingham Comprehensive Cancer Center

Anemia is a common condition in patients with cancer, and its correction through either transfusion with packed red blood cells or the administration of erythropoiesis-stimulating agents (ESAs) is a supportive care measure. The purpose of the guidelines is to operationalize the evaluation and treatment of anemia in cancer patients and to enable patients and clinicians to evaluate treatment options in the context of risks and benefits. The updated guidelines include a number of important changes that respond to new FDA recommendations limiting the use of ESAs in cancer patients. Updates also include new tables on the risks and benefits of ESAs versus red blood cell transfusion and recommendations for administering parenteral iron products.

For the most recent version of the guidelines, please visit

Full access

10.6004/jnccn.2005.0046 Parenteral Iron Therapy: A Single Institution's Experience Over a 5-Year Period Laman Christopher A. * PharmD Silverstein Scott B. † MS Rodgers George M. †‡ MD, PhD 11 2005 3 3 6 6 791 791 795 795 10

Full access

Michael Auerbach and Harold Ballard

Edited by Kerrin G. Robinson

Vaage-Nilsen O Ahlmen J . On the relative safety of parenteral iron formulations . Nephrol Dial Transplant 2004 ; 19 : 1571 – 1575 . 26. Chertow GM Mason PD Vaage-Nilsen O Ahlmen J . Update on adverse drug events associated with

Full access

Jeffrey A. Gilreath, David D. Stenehjem and George M. Rodgers

History of Total Dose Infusion Parenteral iron administration was introduced approximately 60 years ago. In 1954, high-molecular-weight (HMW) iron dextran (Imferon) became available as an intramuscular injection in which a “total dose” could

Full access

Jeffrey A. Gilreath, Daniel S. Sageser, James A. Jorgenson and George M. Rodgers

. Chandler G Harchowal J Macdougall IC . Intravenous iron sucrose: establishing a safe dose . Am J Kid Dis 2001 ; 38 : 988 – 991 . 39. Deicher R Ziai F Cohen G . High-dose parenteral iron sucrose depresses neutrophil intracellular killing

Full access

Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Mark B. Geyer, Ivana Gojo, Avyakta Kallam, Wajih Z. Kidwai, Dwight D. Kloth, Eric H. Kraut, Gary H. Lyman, Sudipto Mukherjee, Lia E. Perez, Rachel P. Rosovsky, Vivek Roy, Hope S. Rugo, Sumithira Vasu, Martha Wadleigh, Peter Westervelt and Pamela S. Becker

suggested, in the short term, broadening the use of ESA therapy with or without parenteral iron supplementation to manage anemia in patients with malignancy requiring blood transfusion support. Response to these agents can be maximized with the addition of

Full access

George M. Rodgers III, Pamela Sue Becker, Morey Blinder, David Cella, Asher Chanan-Khan, Charles Cleeland, Peter F. Coccia, Benjamin Djulbegovic, Jeffrey A. Gilreath, Eric H. Kraut, Ursula A. Matulonis, Michael M. Millenson, Denise Reinke, Joseph Rosenthal, Rowena N. Schwartz, Gerald Soff, Richard S. Stein, Gordana Vlahovic and Alva B. Weir III

functional iron deficiency. Common adverse events after FDA-approved doses of parenteral iron include hypotension, nausea, vomiting and/or diarrhea, pain, hypertension, dyspnea, pruritus, headache, and dizziness. 81 – 83 Most adverse events associated with